AQNEURSA is approved in the U.S. and Europe for neurological manifestations of Niemann-Pick disease type C and in the U.S. as the first and only treatment for Ataxia in patients diagnosed with Ataxia-Telangiectasia
Shionogi is committed to seamless continuity of care for patient communities in the U.S. and to achieving access in Europe
Following the acquisition of RADICAVA ORS® (edaravone), a treatment for amyotrophic lateral sclerosis (ALS), Shionogi has established a strong commercial and medical affairs foundation in rare disease, including expertise serving patients with neurodegenerative diseases. Bringing IntraBio to Shionogi expands that foundation with new capabilities to support the company’s growing rare disease pipeline, which includes clinical programs in Pompe disease, Fragile X syndrome and Jordan’s syndrome, as well as additional early-stage rare neurodegenerative disease programs.
About AQNEURSA®
IMPORTANT SAFETY INFORMATION
- Based on findings from animal reproduction studies, AQNEURSA may cause harm to your unborn baby when administered during pregnancy.
- Your healthcare provider will check to make sure you are not pregnant before starting treatment with AQNEURSA.
- Use effective birth control (contraception) during treatment with AQNEURSA and for 7 days after stopping treatment to avoid pregnancy.
- If you become pregnant while taking AQNEURSA, inform your healthcare provider immediately to discuss potential risks and alternative treatments.
- It is not known if AQNEURSA or its metabolites pass into human or animal milk or effect breastmilk production.
- Tell your healthcare provider if you are taking certain medications called P-gp substrates, N-acetyl-DL-leucine or N-acetyl-D-leucine. If you are not sure if you are taking these medicines, talk to your healthcare provider or pharmacist.
About Niemann-Pick Disease Type C
About Ataxia-Telangiectasia
About Shionogi & Co., Ltd.
About Shionogi Inc.
About Shionogi B.V.
About Shionogi in Rare Disease
Forward-Looking Statements
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
U.S. Media: ShionogiCommunications@shionogi.com
Shionogi Europe Press Office: pressoffice@shionogi.eu